PolyPid (NASDAQ:PYPD) Coverage Initiated at Rodman & Renshaw

Rodman & Renshaw started coverage on shares of PolyPid (NASDAQ:PYPD) in a research report issued on Tuesday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $13.00 price target on the stock. Rodman & Renshaw’s target price indicates a potential upside of 312.70% from the company’s previous close.

PYPD has been the topic of several other reports. HC Wainwright lowered their price objective on PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a research report on Thursday, December 26th. Craig Hallum started coverage on PolyPid in a report on Monday, November 4th. They issued a “buy” rating and a $10.00 price objective for the company.

PolyPid Price Performance

Shares of NASDAQ:PYPD opened at $3.15 on Tuesday. The company has a market capitalization of $15.12 million, a PE ratio of -0.40 and a beta of 1.32. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.00 and a quick ratio of 1.00. PolyPid has a 1-year low of $2.37 and a 1-year high of $7.00. The business has a fifty day moving average price of $3.13 and a 200-day moving average price of $3.37.

Institutional Trading of PolyPid

An institutional investor recently bought a new position in PolyPid stock. Stonepine Capital Management LLC acquired a new position in PolyPid Ltd. (NASDAQ:PYPD) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 138,504 shares of the company’s stock, valued at approximately $476,000. Stonepine Capital Management LLC owned 2.89% of PolyPid as of its most recent SEC filing. 26.47% of the stock is owned by hedge funds and other institutional investors.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.